top of page

MRNA Showing Leadership Potential

  • Writer: TLivingstonBlog
    TLivingstonBlog
  • Sep 23, 2021
  • 2 min read

I always try to make my trading as simple as possible. I often ask myself, “What’s a product that everyone is currently using that has the potential to drastically change people’s lives?” Last year, Zoom was a great example of this as it was the go-to video conferencing app for millions around the world who sought to stay in touch with colleges, friends, and family during the COVID-19 pandemic.

This year, I believe Moderna is a stock that most resembles Zoom in 2020. Just like Zoom was essential to stay in touch with friends and family last year, many cities such as New York are requiring people to show proof of vaccination in order to enter gyms, restaurants, or other large venues. In addition, many employers are requiring their employees to get vaccinated in order to stay on the payroll. All of this bodes well for Moderna which seems to have the most effective COVID-19 vaccine.

Last quarter, Moderna produced triple-digit earnings and sales growth as millions around the world got vaccinated. Strong earnings and sales are likely to continue throughout the remainder of 2021 as more and more people choose to get vaccinated in an effect to gain some level of normalcy in this COVID-19 world. MRNA also has some positive supply and demand features as management owns 19% of Moderna’s shares. Moreover, fund ownership has steadily been increasing this year as MRNA’s addition to the S&P 500 caused many funds to begin buying it.

I initially bought Moderna as it broke out above the $190 range, but sold it up 45% and thus missed a large chunk of its’ latest move. However, when I sell a stock with fundamentals as strong as Moderna, I always make a note to keep it on my watchlist in case it sets up again. MRNA looks to be doing just that. While looking at its’ chart, Moderna is forming a tiny cup and handle pattern. However, it is also exhibits "high-tight flag" type action as it more than doubled from $190 to over $400 quickly, and then consolidated in an extremely constructive manner. I particularly like the consistent support MRNA has seen above the 10-week line over the last few months followed by the tight action over the last few weeks. All of this is a clear sign of institutional support. I will be monitoring MRNA extremely closely over the next few days for an entry point.





Disclaimer: This information is issued solely for informational and educational purposes and does not constitute an offer to sell or a solicitation of an offer to buy securities. None of the information contained in this post constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. From time to time, the content creator or its affiliates may hold positions or other interests in securities mentioned in this blog or the associated Twitter and Instagram feeds. The stock or stocks presented are not to be considered a recommendation to buy any stock or stocks. This material does not take into account your particular investment objectives. Investors should consult their own financial or investment adviser before trading or acting upon any information provided. Past performance is not indicative of future results.

Comments


Commenting on this post isn't available anymore. Contact the site owner for more info.

Statement on Accessibility

We are working to make this website easier to access for people with disabilities, and will follow the Web Content Accessibility Guidelines 2.0. ​ If you need assistance with a particular page or document on our current site, please contact tlivingstonblog@gmail.com to request assistance.

Join My Mailing List

Hypothetical Performance Disclosure: Hypothetical performance results have many inherent limitations, some of which are described below. No representation is being made that any account will or is likely to achieve profits or losses similar to those shown; in fact, there are frequently sharp differences between hypothetical performance results and the actual results subsequently achieved by any particular trading program. One of the limitations of hypothetical performance results is that they are generally prepared with the benefit of hindsight. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. for example, the ability to withstand losses or to adhere to a particular trading program in spite of trading losses are material points which can also adversely affect actual trading results. There are numerous other factors related to the markets in general or to the implementation of any specific trading program which cannot be fully accounted for in the preparation of hypothetical performance results and all which can adversely affect trading results.

Risk Disclosure: Futures and forex trading contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results.

Crypto CFTC advisories

bottom of page